Publications (International)

NOTE: The US Food and Drug Administration (FDA) approved the premarket approval application (PMA) for SIR-Spheres microspheres in March 2002 for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUdR (Floxuridine).

Colorectal Cancer
Review Articles
Dosimetry
Hepatocellular Cancer
Breast Cancer
Various

Colorectal Cancer

1. Lim, L., Gibbs, P., Yip, D., et al. (2005). "Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies." Internal Medicine Journal 35: 222 - 227.


2. Murthy, R., Xiong, H., Nunez, R., et al. (2005). "Yttrium 90 Resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: Preliminary results." Journal of Vascular and Interventional Radiology 16: 937 - 945.

NOTE: The information below covers a use that has not been approved by the FDA.
3. Wong, C. O., Qing, F., Savin, M., et al. "Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F] fluorodeoxyglucose positron emission tomographic imaging". J Vasc Interv Radiol 2005; 16:1101-1106.

NOTE: The information below covers a use that has not been approved by the FDA.
4. Popperl, G., Helmberger, T., et al. "Selective internal radiation therapy with SIR-Spheres microspheres in patients with nonresectable liver tumors". Cancer Biotherapy & Radiopharmaceuticals 20(2): 200-208. 2005

NOTE: The information below covers a use that has not been approved by the FDA.
5. Liu, D., Salem, R., Bui, J., et al. "Angiographic considerations in patients undergoing liver- directed therapy". J Vasc Interv Radiol 2005; 16:911-935


NOTE: The information below covers a use that has not been approved by the FDA.
6. Murthy, R., Nunez, R., et al. "Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications". RadioGraphics 2005; 25:S41-S55.


7. Van Hazel, G., Blackwell, A., Anderson, J., et al. (2004). "Randomised phase 2 trial of SIR-Spheres microspheres plus Fluorouracil/Leucovorin chemotherapy versus Fluorouracil/Leucovorin chemotherapy alone in advanced colorectal cancer." Journal of Surgical Oncology 88: 78 - 85.


8. Stubbs, R. and Wickremesekera, S. (2004). "Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases." HPB 6(3): 133 - 139.


9. Yip, D., Allen, R., Ashton, C., et al. (2004). "Letter: Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer." Journal of Gastroenterology and Hepatology 19(3): 347 - 349.


10. Liu, L., Zhang, W. and Jiang, H. (2003). "Current treatment for liver metastases from colorectal cancer." World Journal of Gastroenterology 9(2): 193 - 200.


11. Gray, B., Van Hazel, G., Hope, M., et al. (2001). "Randomised trial of SIR-Spheres microspheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer." Annals of Oncology 12: 1711 - 1720.


12. Stubbs, R., Cannan, R. and Mitchell, A. (2001). "Selective Internal Radiation Therapy with yttrium-90 microspheres for extensive liver metastases." Journal of Gastrointestinal Surgery 5: 294 - 302.


13. Moroz, P., Anderson, J., Van Hazel, G., et al. (2001). "Effect of Selective Internal Radiation Therapy and Hepatic Arterial Chemotherapy on Normal Liver Volume and Spleen Volume." Journal of Surgical Oncology 78: 248 - 252.


14. Gray, B., Van Hazel, G., Buck, M., et al. (2000). "Treatment of colorectal liver metastases with SIR-Spheres microspheres plus chemotherapy." GI Cancer 3: 249 - 257.

top

Review Articles

NOTE: The information below covers a use that has not been approved by the FDA.

1. Coldwell, D. and Sewell, P. (2005). "The Expanding Role of Interventional Radiology inthe Supportive Care of the Oncology Patient: From diagnosis to Therapy." Seminars in Oncology 32: 169 - 173.

NOTE: The information below covers a use that has not been approved by the FDA.
2. Moroz, P. and Gray, B. (2000). "Radiotherapy in the Treatment of Advanced Liver Cancer: Current Status and Future Directions." Asian Journal of Surgery 23(1): 32 - 41.


3. Stubbs, R. and Cannan, R. (1999). "Active treatment of colorectal hepatic metastases." New Zealand Family Physician 26.

top

Dosimetry

NOTE: The information below covers a use that has not been approved by the FDA.
1. Kennedy, A., Nutting, C., Coldwell, D., et al. (2004). "Pathologic response and microdosimetry of ⁹⁰Y microspheres in man: review of four explanted whole livers." International Journal of Radiation Oncology, Biology and Physics 60(5): 1552-1563.

top

Hepatocellular Cancer

NOTE: The information below covers a use that has not been approved by the FDA.
1. Lau, W., Ho, S., Yu, S., et al. (2004). "Salvage surgery following downstaging of unresectable hepatocellular carcinoma." Annals of Surgery 240: 299 - 305.


2. Thamboo, T., Tan, K., Wang, S., et al. (2003). "Extra-hepatic embolisation of Y-90 microspheres from selective internal radiation therapy (SIRT of the liver." Pathology 35(4): 351 - 353.


3. Szeto, C., Wong, T., Leung, C., et al. (2001). "Selective internal radiation therapy by yttrium-90 microspheres for hepatocellular carcinoma after renal transplantation." Clinical Transplantation 15: 284 - 288.


4. Ho, S., Lau, J. and Leung, T. (2001). "Intrahepatic Y-90 microspheres for hepatocellular carcinoma." Journal of Nuclear Medicine 42: 1587 - 1588.


5. Lau, W., Ho, S., Leung, T., et al. (2001). "What determines survival duration in hepatocellular carcinoma treated with intraarterial yttrium-90 microspheres?" Hepato-Gastroenterology 48: 338 - 340.


6. Stubbs, R., Cannan, R., Mitchell, A., et al. (1999). "An initial experience with selective internal radiation therapy (SIRT) for non-resectable colorectal liver metastases." Gastrointestinal Cancer 3(2): 135 - 143.


7. Ho, S., Johnson, P., Leung, W., et al. (1998). "Combating hepatocellular carcinoma with an integrated approach." Chinese Medical Journal 112(1): 80 - 83.


8. Ho, S., Lau, W., Leung, T., et al. (1997). "Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer." European Journal of Nuclear Medicine 24: 293 - 298.


9. Lau, W., Leung, W., Ho, S., et al. (1994). "Treatment of inoperative hepatocellular carcinoma with intra-arterial yttrium-90 microspheres: a phase 1 and 2 study." British journal of Cancer 70: 994 - 999.

top

Breast Cancer 

NOTE: The information below covers a use that has not been approved by the FDA.
1. Rubin, D., Nutting, C. and Jones, B. (2004). "Metastatic breast cancer in a 54-year-old woman: Integrative treatment with yttrium-90 radioembolization." Integrative Cancer Therapies 3: 262 - 267.

top

Various

NOTE: The information below covers a use that has not been approved by the FDA.
1. Wickremesekera, J., Chen, W., Cannan, R., et al. (2001). "Serum proinflammatory cytokine response in patients with advanced liver tumors following selective internal radiation therapy (SIRT) with yttrium-90 microspheres." International journal of Radiation Oncology, Biology and Physics 49(4): 1015 - 1021.

top